1. HOME

Background of Merger

Celltrion is set to streamline its biosimilar subsidiary companies into a unified entity to respond swiftly to the rapidly growing and competitive global market. This initiative aims to establish a foundation for evolving into a global big pharmaceutical company. The merger holds significant importance in accelerating the securing of future growth drivers for Celltrion. Through this merger, we aim to grow into a leading global big pharma, making advancements into novel drugs beyond biosimilars.

Change in Ownership Structure after Merger

  • Pre-Merger

    Celltrion Holdings

    • 20.1%
    • 24.3%

    • Celltrion

    • Celltrion
      Healthcare

    • 54.8%

    Celltrion Pharm

  • Post-Merger

    Celltrion Holdings

    • 21.6%

    • Celltrion
      (MergeCo)

    • 54.8%

    Celltrion Pharm

Merger Effects

  • Large-Scale Investment in Strategic Focus Area
    • Secure integrated group resources via vertical integration
    • Deploy integrated group resources for large-scale investments
  • Maximize Market Share Based on Cost Competitiveness
    • Strengthen development and sales cooperation through vertical integration
    • Launch distinctive products by quickly identifying unmet market needs
  • Enhancing Transparency through Simplification of the Transaction Structure
    • Improve earnings visibility by elimination of related party transactions
    • Improve cost structure through change in inventory recognition

Merger Vision

Increasing Market Presence via Biosimilar Expansion & Product Differentiation

Secure competitiveness in the US market and establish a global brand through various marketing strategies, including product bundling Pursue a distinctive differentiation strategy to secure robust competitive edge by introducing new formulation, dosage and administration Showcasing world-class pipeline development capabilities by successfully commercializing 22 products by 2030

Transcending the Realm of Biosimilars to Emerge as an Innovator

Accelerating novel drug development by leveraging leading antibody technology Applying novel drug platform technology to biosimilar development Actively pursuing synergy opportunities through M&A from the second half of 2023 Zymfentra to emerge as a highly-profitable blockbuster novel drug

Completing the Biopharma Value Chain

Full integration of the biopharma value chain with direct sales network Amplifying profitability by broadening reach into target countries and expanding direct sales coverage Securing cost competitiveness & stable supply with in-house production facilities

Digital Health: Building Virtuous Circle in Drug Development & New Business

Selecting highly synergistic & viable business areas and leveraging Celltrion's strength in extensive clinical and genomic data to drive business expansion Driving innovation in diagnosis and analysis and expanding remote diagnosis and care

Enhancement of Shareholder Value

Celltrion anticipates an increase in both revenue and profit through the expansion of its biosimilar pipeline, successful commercialization of new drugs and improved profitability in direct sales after the merger. Based on this, the company plans to secure the necessary resources for shareholder returns effectively and strengthen its shareholder return policy.

Shareholder Return Policy

Increase Revenue & Profitability via Merger

  • Expand Biosimilar Pipeline

  • Successfully Commercialize Novel Drugs

  • Enhance Profitability by Direct Sales

Gradual Expansion of Cash Dividend Portion

Increase in Shareholder Return